Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. [electronic resource]
Producer: 20070405Description: 110-115 p. digitalISSN:- 0923-7534
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carcinoma, Large Cell -- drug therapy
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Carcinoma, Squamous Cell -- drug therapy
- Deoxycytidine -- administration & dosage
- Female
- Humans
- Infusions, Intravenous
- Lung Neoplasms -- drug therapy
- Male
- Maximum Tolerated Dose
- Middle Aged
- Paclitaxel -- administration & dosage
- Prognosis
- Survival Rate
- Treatment Outcome
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.